A phase 2 study reveals promising efficacy and safety of TKI and inotuzumab ozogamicin therapy for newly diagnosed Ph+ ALL, achieving high response rates.
Anand A. Patel, MD
Advertisement
Anand A. Patel, MD, is an assistant professor of medicine at the University of Chicago.
Articles by Anand A. Patel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
2
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
3
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5
